US Patent

US8138199 — Use of bi-aryl meta-pyrimidine inhibitors of kinases

Method of Use · Assigned to TargeGen Inc · Expires 2028-06-30 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of biaryl meta-pyrimidine compounds that inhibit kinases, such as Jak kinase family members.

USPTO Abstract

The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.

Drugs covered by this patent

Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2607`	—	Inrebic

Patent Metadata

Patent number: US8138199
Jurisdiction: US
Classification: Method of Use
Expires: 2028-06-30
Drug substance claim: No
Drug product claim: No
Assignee: TargeGen Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.